Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study-Reference-Cited by-同舟云学术

Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study

Published:2022-04-14 Issue: Volume: Page:jnumed.121.263072
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Gafita Andrei,Rauscher Isabel,Weber Manuel,Hadaschik Boris,Wang Hui,Armstrong Wesley Robert,Tauber Robert,Grogan Tristan R.,Czernin Johannes,Rettig Matthew B.,Herrmann Ken,Calais Jeremie,Weber Wolfgang A.,Benz Matthias,Fendler Wolfgang P.,Eiber Matthias

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the Heterogeneity of Response of [68Ga] Ga-PSMA-11 PET/CT Lesions in Patients With Biochemical Recurrence of Prostate Cancer;Clinical Genitourinary Cancer;2024-10

2. Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-29

3. PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer;EJNMMI Reports;2024-08-19

4. Impact of Posttreatment SPECT/CT on Patient Management During¹⁷⁷Lu-PSMA-617 Radiopharmaceutical Therapy;Journal of Nuclear Medicine;2024-08-08

5. Impact of definitive radiotherapy on metabolic response measured with ⁶⁸Ga‐PSMA‐PET/CT in patients with intermediate‐risk prostate cancer;The Prostate;2024-08-06